Sessions
Click here for a pdf of the program schedule
Monday, January 19, 2009
9:15am - 10:30am
Grand Ballroom West
This session will focus on the current environment for international, cross-border partnering and M&A and the outlook for 2009. With the current challenging financing environment, corporate investment, partnering and M&A may be one of the few bright spots of activity in 2009. With big pharma pipeline needs and the acute needs for capital among biotechs, 2009 promises to be both a tremendous challenge and a great opportunity for all companies. If you are looking for a strategic transaction, how can you get the attention of the pharma companies? At the pharma companies, how will you develop your priorities and focus your resources to sort through the various opportunities. The panel will include key dealmakers and will discuss their perspectives on the outlook for partnering and M&A activity.
Monday, January 19, 2009
3:15pm - 4:30pm
Tarragon Room
Reimbursement for innovative therapeutics is a key component for investors and companies in terms of evaluating returns and opportunities for investment. For example, the pricing practices that the Japanese government has instituted are leading to greater adoption of generics and [also questions about the use of proprietary named-therapies versus their generic equivalents]. This panel will discuss trends in reimbursement, an assessment of how investors are considering these changes and companies’ approaches to these issues.
Tuesday, January 20, 2009
9:15am - 10:30am
Tarragon Room
The past 5 years has seen a remarkable wave of consolidation in the Japanese pharma industry. This re-ordering of the players in the industry means that while there are fewer players, those that remain have greater resources and ability to conduct business on a global scale. As a result of these changes, though, should emerging biotech firms adjust their partnering and alliance strategies? How should these companies approach the “new” Japanese industry? Should they have concerns that a potential partner might be acquired or merged? This panel will discuss these considerations.
Tuesday, January 20, 2009
3:15pm - 4:30pm
Tarragon Room
This session will examine the activities and interests of some of the most active VC’s operating in Asian deal making: corporate VC’s. Given the structure that supports corporate VCs, many have been engaged in deal development in Asia.